Cargando…

Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review

Albutrepenonacog-alfa (Idelvion(®), CSL Behring) is a recombinant fusion protein in which the recombinant FIX (rFIX) links a recombinant human albumin, extending the half-life of rFIX even beyond 100 hours. In 2016, this drug was approved worldwide for the treatment of pediatric and adult persons wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pasca, Samantha, Zanon, Ezio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484766/ https://www.ncbi.nlm.nih.gov/pubmed/36132333 http://dx.doi.org/10.2147/DDDT.S236788

Ejemplares similares

Fc-fusion technology and recombinant FVIII and FIX in the management of the hemophilias
por: Mancuso, Maria Elisa, et al.
Publicado: (2014)

Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient’s Perspectives
por: Pasca, Samantha
Publicado: (2022)

Major cardiac surgery with recombinant FIX Fc fusion protein replacement in hemophilia B: a case report
por: Bohn, Jan-Paul, et al.
Publicado: (2022)

Acquired Hemophilia A: An Update on the Etiopathogenesis, Diagnosis, and Treatment
por: Zanon, Ezio
Publicado: (2023)

Managing Relevant Clinical Conditions of Hemophilia A/B Patients
por: Morfini, Massimo, et al.
Publicado: (2023)

Damoctocog Alfa Pegol for Hemophilia A Prophylaxis: An Italian Multicenter Survey
por: Zanon, Ezio
Publicado: (2023)

Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B
por: Dietrich, Barbara, et al.
Publicado: (2013)

The Molecular Basis of FIX Deficiency in Hemophilia B
por: Shen, Guomin, et al.
Publicado: (2022)

Rehabilitation management of a triceps surae muscle injury in a young male with haemophilia A and high-titre inhibitors
por: Frizziero, Antonio, et al.
Publicado: (2021)

Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE(®)) in the management of hemophilia A
por: Shapiro, Amy D
Publicado: (2007)

Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A
por: Pipe, Steven
Publicado: (2009)

Real-World Use of Albutrepenonacog Alfa, A Recombinant Coagulation Factor IX Albumin Fusion Protein, for Personalized Prophylaxis in Japanese Individuals With Hemophilia B: A Case Series
por: Nagao, Azusa, et al.
Publicado: (2023)

Regenerative Surgery with Dental Implant Rehabilitation in a Haemophiliac Patient
por: Bacci, Christian, et al.
Publicado: (2021)

Treatment of hemophilia B: focus on recombinant factor IX
por: Franchini, Massimo, et al.
Publicado: (2013)

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2023)

Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B
por: Shapiro, Amy D., et al.
Publicado: (2018)

GlycoPEGylated recombinant factor IX for hemophilia B in context
por: Santagostino, Elena, et al.
Publicado: (2018)

Biodistribution of recombinant factor IX, extended half-life recombinant factor IX Fc fusion protein, and glycoPEGylated recombinant factor IX in hemophilia B mice
por: van der Flier, Arjan, et al.
Publicado: (2023)

How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report
por: Zanon, Ezio, et al.
Publicado: (2020)

Joint Dysfunction as a Cause of Spontaneous Subclinical Bleeding in Infants with Hemophilia
por: Boccalandro, Elena Anna, et al.
Publicado: (2023)

Updates on Novel Non-Replacement Drugs for Hemophilia
por: Gualtierotti, Roberta, et al.
Publicado: (2022)

Consensus Review of the Treatment of Cardiovascular Disease in People With Hemophilia A and B
por: Ferraris, Victor A., et al.
Publicado: (2015)

Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice
por: Toby, Garabet G., et al.
Publicado: (2016)

Recombinant factor IX‐Fc fusion protein in severe hemophilia B: Patient‐reported outcomes and health‐related quality of life
por: O’Donovan, Mairead, et al.
Publicado: (2021)

RNAi for the Treatment of People with Hemophilia: Current Evidence and Patient Selection
por: Boyce, Sara, et al.
Publicado: (2023)

Health Related Quality of Life and Psychopathological Symptoms in People with Hemophilia, Bloodborne Co-Infections and Comorbidities: An Italian Multicenter Observational Study
por: Schiavoni, Mario, et al.
Publicado: (2023)

The bleeding phenotype in people with nonsevere hemophilia
por: Kloosterman, Fabienne R., et al.
Publicado: (2022)

Favorable pharmacokinetics in hemophilia B for nonacog beta pegol versus recombinant factor IX‐Fc fusion protein: A randomized trial
por: Escuriola Ettingshausen, Carmen, et al.
Publicado: (2019)

Recombinant FVIII: the milestone of modern hemophilia treatment
por: Mannucci, Pier Mannuccio
Publicado: (2023)

Recombinant factor VIII in the management of hemophilia A: current use and future promise
por: Powell, Jerry S
Publicado: (2009)

IDEAL study: A real‐world assessment of pattern of use and clinical outcomes with recombinant coagulation factor IX albumin fusion protein (rIX‐FP) in patients with haemophilia B in Italy
por: Tagliaferri, Annarita, et al.
Publicado: (2022)

Substantially improved pharmacokinetics of recombinant human butyrylcholinesterase by fusion to human serum albumin
por: Huang, Yue-Jin, et al.
Publicado: (2008)

Intramural Hematoma of Gastrointestinal Tract in People with Hemophilia A and B
por: Teng, Wei-Jung, et al.
Publicado: (2023)

Discovery of an Orally Effective Factor IX-Transferrin Fusion Protein for Hemophilia B
por: Xie, Chen, et al.
Publicado: (2019)

Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia B
por: Djambas Khayat, Claudia
Publicado: (2016)

New developments in the management of moderate-to-severe hemophilia B
por: Nazeef, Moniba, et al.
Publicado: (2016)

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
por: Krishnamoorthy, Sriram, et al.
Publicado: (2015)

Direct-to-consumer Marketing to People with Hemophilia
por: Kucab, Philip, et al.
Publicado: (2016)

Comprehensive management of hemophilia /
Publicado: (1976)

Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one‐stage clotting assays
por: Horn, C., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bdbvapmtk6h2rsp87vt7obqmka